Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndrome

Int J Hematol. 2014;99(5):663-7. doi: 10.1007/s12185-014-1527-9. Epub 2014 Feb 20.

Abstract

Sweet's syndrome is a rare condition with potentially disabling implications, characterized by painful skin lesions due to neutrophilic dermal infiltration and systemic inflammatory symptoms. A significant proportion of cases is malignancy associated. Hematologic neoplasms, particularly acute myeloid leukemia and myelodysplastic syndromes, are the most commonly associated malignant conditions. Here, we describe the first case of clinical remission of refractory Sweet's syndrome following hypomethylating therapy with azacytidine in a patient with myelodysplastic syndrome who concurrently obtained a complete hematologic response.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Azacitidine / therapeutic use*
  • Biopsy
  • Bone Marrow / pathology
  • Humans
  • Male
  • Myelodysplastic Syndromes / complications*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / therapy
  • Skin / pathology
  • Sweet Syndrome / complications*
  • Sweet Syndrome / diagnosis
  • Sweet Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Azacitidine